论文部分内容阅读
目的:探讨纤溶酶联合阿司匹林对急性脑梗死患者的血液黏度和临床疗效的影响。方法:收集2016年10月至2020年6月大连市第三人民医院70例轻中度急性脑梗死患者，将患者按照随机数字表法分为对照组和治疗组，各35例。对照组给予阿司匹林口服加上与治疗组等量的0.9%氯化钠静脉滴注，治疗组给予阿司匹林基础上加用纤溶酶静脉滴注。两组均给予管理血糖、血压、稳定斑块及改善循环等对症治疗，均治疗10 d。治疗前后分别对两组进行血液黏度检测和神经功能缺损评分。结果:与基线值相比，对照组治疗后血液黏度示所有剪切速率较治疗前略有下降，但差异无统计学意义（n P>0.05）。治疗组所有剪切速率均较治疗前下降（n P<0.05），且较对照组血液黏度作用效果显著（n P0.05). In the treatment group, all shear rates decreased compared with that before treatment (n P<0.05), and the effect of WBV was significant compared with that of the control group (n P<0.05). The improvement of neurological function in the treatment group was better than that in the control group. The significant efficiency and the total effective rate in the treatment group were significantly higher than those in the control group: 34.3% (12/35) vs. 25.7% (9/35), 88.6% (31/35) vs.71.4% (25/35).n Conclusions:Fibrinogenase combined with aspirin in the treatment of acute cerebral infarction patients can safely and effectively reduce blood viscosity and improve clinical symptoms.